Calidi Biotherapeutics Inc. Featured for Breakthrough Cancer Treatment Platform
July 8th, 2025 2:07 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been highlighted for its innovative genetic medicine platform targeting cancer, offering a novel approach to combat the anticipated rise in global cancer diagnoses.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in a NetworkNewsWire editorial for its precision genetic medicine platform, which utilizes engineered viruses to target both primary and metastatic cancer tumors. With projections indicating that global cancer diagnoses could reach 35 million annually by 2050, Calidi's technology presents a significant advancement in addressing the urgent need for effective cancer treatments. The platform's ability to deliver potent genetic therapies directly to cancer sites marks a potential turning point in oncology, offering a new avenue for treatment that could disrupt traditional cancer therapies. For more details on this development, visit https://ibn.fm/GZS7L.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
